Before the in vitro affinity study, cytotoxicity of the GRPR-targeted nanobubbles on GRPR+ prostate cancer cells, PC3, was evaluated using Presto Blue cell viability assay. The gene discussed is GRPR; the disease is prostate carcinoma.